Astellas U.S. Unit Settles Off-Label Pediatric Use Case For $7.3 Million
This article was originally published in PharmAsia News
Astellas Pharma, the U.S. unit of the Japan-based drug maker, has agreed to pay a $7.3 million fine for promoting pediatric use of its Mycamine (mycafungin) drug for treating invasive fungal infections.
You may also be interested in...
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
Latest EU company news: Sanofi grows OTC portfolio in France and Italy with ColdZyme; Germany's WindStar Medical gets UK owners; and France's Ipsen continues to fell effects of COVID-19 on sales.
Combination of antibody therapy and Gilead's Veklury fails to show potential in patients with advanced disease.